Origami Therapeutics, Inc.

Oral drugs to halt neurodegeneration

Y CombinatorWinter 2022ActiveHealthcareTherapeuticsBiotechTherapeuticsDrug discovery

What they do

Problem

Neurodegenerative diseases like Huntington’s lack effective treatments that can halt progression by removing toxic disease-driving proteins in the brain.

Solution

The company develops oral small-molecule protein degraders discovered using proprietary human disease models to eliminate toxic proteins and slow or stop neurodegeneration.

Who it's for

Pharmaceutical and biotechnology stakeholders developing therapeutics for patients with neurodegenerative diseases, starting with Huntington’s disease.

Founders

Beth Hoffman

Founder

At Origami Therapeutics, Dr. Hoffman is creating a new approach to drug discovery for neurodegenerative diseases. Prior to Origami, she was a Research & Development executive at Vertex Pharmaceuticals, Amgen and Eli Lilly. She has made major contributions to >30 clinical programs in neurology, pain and psychiatry and to four marketed drugs for Cystic Fibrosis. Dr. Hoffman received her A.B. in Molecular Biology from Wellesley College and a Ph.D. in Cell Biology from the Johns Hopkins University.

LinkedIn · X